340 related articles for article (PubMed ID: 25824237)
1. The effects of glucose-lowering therapies on diabetic kidney disease.
Agrawal V; Giri C; Solomon RJ
Curr Diabetes Rev; 2015; 11(3):191-200. PubMed ID: 25824237
[TBL] [Abstract][Full Text] [Related]
2. Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers.
Tong L; Adler S
Postgrad Med; 2018 May; 130(4):381-393. PubMed ID: 29667921
[TBL] [Abstract][Full Text] [Related]
3. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
Lo C; Toyama T; Wang Y; Lin J; Hirakawa Y; Jun M; Cass A; Hawley CM; Pilmore H; Badve SV; Perkovic V; Zoungas S
Cochrane Database Syst Rev; 2018 Sep; 9(9):CD011798. PubMed ID: 30246878
[TBL] [Abstract][Full Text] [Related]
4. DPP-4 Inhibitors in Diabetic Patients with Chronic Kidney Disease and End-Stage Kidney Disease on Dialysis in Clinical Practice.
Abe M; Okada K
Contrib Nephrol; 2015; 185():98-115. PubMed ID: 26023019
[TBL] [Abstract][Full Text] [Related]
5. [Newer anti - diabetic therapies and chronic kidney disease].
Di Lullo L; Ronco C; Barbera V; Cozzolino M; Santoboni F; Villani A; De Pascalis A; Bellasi A
G Ital Nefrol; 2017; 34(1):. PubMed ID: 28177092
[TBL] [Abstract][Full Text] [Related]
6. Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects.
Sloan LA
J Diabetes; 2019 Dec; 11(12):938-948. PubMed ID: 31318152
[TBL] [Abstract][Full Text] [Related]
7. Diabetic nephropathy: new approaches for improving glycemic control and reducing risk.
Schernthaner G; Schernthaner GH
J Nephrol; 2013; 26(6):975-85. PubMed ID: 23807645
[TBL] [Abstract][Full Text] [Related]
8. Evidence-based treatment of hyperglycaemia with incretin therapies in patients with type 2 diabetes and advanced chronic kidney disease.
Tuttle KR; McGill JB
Diabetes Obes Metab; 2020 Jul; 22(7):1014-1023. PubMed ID: 32009296
[TBL] [Abstract][Full Text] [Related]
9. How are patients with type 2 diabetes and renal disease monitored and managed? Insights from the observational OREDIA study.
Penfornis A; Blicklé JF; Fiquet B; Quéré S; Dejager S
Vasc Health Risk Manag; 2014; 10():341-52. PubMed ID: 24966684
[TBL] [Abstract][Full Text] [Related]
10. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
[TBL] [Abstract][Full Text] [Related]
11. New pharmacological strategies for protecting kidney function in type 2 diabetes.
Muskiet MHA; Wheeler DC; Heerspink HJL
Lancet Diabetes Endocrinol; 2019 May; 7(5):397-412. PubMed ID: 30579729
[TBL] [Abstract][Full Text] [Related]
12. Comparison of efficacy and safety of three novel hypoglycemic agents in patients with severe diabetic kidney disease: A systematic review and network meta-analysis of randomized controlled trials.
Li Y; Hu Y; Huyan X; Chen K; Li B; Gu W; Mu Y
Front Endocrinol (Lausanne); 2022; 13():1003263. PubMed ID: 36353233
[TBL] [Abstract][Full Text] [Related]
13. Hypoglycemics for the treatment of type 2 diabetes in patients with chronic kidney disease: a focus on new agents.
Fang V; Wazny LD; Raymond CB
CANNT J; 2012; 22(1):30-6; quiz 37-8. PubMed ID: 22558681
[No Abstract] [Full Text] [Related]
14. GLP-1 Receptor Agonists in Diabetic Kidney Disease.
Michos ED; Tuttle KR
Clin J Am Soc Nephrol; 2021 Oct; 16(10):1578-1580. PubMed ID: 33849933
[No Abstract] [Full Text] [Related]
15. Not only incretins for diabetic kidney disease-beneficial effects by DPP-4 inhibitors.
Nangaku M; Wanner C
Kidney Int; 2021 Feb; 99(2):318-322. PubMed ID: 33509354
[No Abstract] [Full Text] [Related]
16. Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease.
McGill JB; Yki-Järvinen H; Crowe S; Woerle HJ; von Eynatten M
Diab Vasc Dis Res; 2015 Jul; 12(4):249-57. PubMed ID: 25941160
[TBL] [Abstract][Full Text] [Related]
17. Current findings on the efficacy of incretin-based drugs for diabetic kidney disease: A narrative review.
Mima A; Nomura A; Fujii T
Biomed Pharmacother; 2023 Sep; 165():115032. PubMed ID: 37331253
[TBL] [Abstract][Full Text] [Related]
18. Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease.
Chen JJ; Wu CY; Jenq CC; Lee TH; Tsai CY; Tu HT; Huang YT; Yen CL; Yen TH; Chen YC; Tian YC; Yang CW; Yang HY
JAMA Netw Open; 2022 Mar; 5(3):e221169. PubMed ID: 35254430
[TBL] [Abstract][Full Text] [Related]
19. Economic benefit of prescribing an adjusted renal dose of dipeptidyl peptidase IV inhibitors in type 2 diabetes patients with chronic kidney disease.
Moon SJ; Cho YM
J Diabetes; 2020 Sep; 12(9):645-648. PubMed ID: 32436296
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of Incretin-Based Therapies in Patients With Type 2 Diabetes Mellitus and CKD: A Systematic Review and Meta-analysis.
Howse PM; Chibrikova LN; Twells LK; Barrett BJ; Gamble JM
Am J Kidney Dis; 2016 Nov; 68(5):733-742. PubMed ID: 27528374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
